WIC
KITE

Woodmont Investment Counsel’s Kite Pharma, Inc. KITE Stock Holding History

Woodmont Investment Counsel’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-300
Closed -$17K – 717
2016
Q3 		$17K Buy
+300
New +$16.7K ﹤0.01% 393

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Woodmont Investment Counsel's KITE Position: Q4 2016 in Review

Woodmont Investment Counsel sold out of Kite Pharma, Inc. (KITE) in Q4 2016, closing a stake of 300 shares — an estimated $17K sold.

Woodmont Investment Counsel first reported a position in KITE in Q3 2016 and held it in 1 quarter. The position peaked at $17K in Q3 2016. 184 funds tracked by Wall St. Rank hold KITE as of Q4 2016.

  • Woodmont Investment Counsel reported no remaining Kite Pharma, Inc. position as of Q4 2016 after selling out during the quarter.
  • Woodmont Investment Counsel sold 300 Kite Pharma, Inc. shares in Q4 2016, an estimated $17K.
  • Woodmont Investment Counsel first reported a position in Kite Pharma, Inc. in Q3 2016 and held it in 1 quarter.
  • Woodmont Investment Counsel's Kite Pharma, Inc. position peaked at $17K in Q3 2016.
  • 184 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2016.

Based on Woodmont Investment Counsel's 13F filing for Q4 2016, filed 13 Feb 2017.